TECFIDERA clinical trials

Open-Label, Randomized, Multicenter, Multi-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to Less Than 18 Years of Age with Relapsing-Remitting Multiple Sclerosis with Optional Open-Label Extension (CONNECT)

This study looks at a medicine called BG00012 for children and teenagers aged 10 to under 18 with a type of multiple sclerosis (MS). It aims to see how well it works in preventing new MS brain lesions and to check its safety, comparing it with an existing treatment.